

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2011298361 B2

(54) Title
5-HT2B receptor antagonists

(51) International Patent Classification(s)
C07D 211/58 (2006.01) **A61P 11/00** (2006.01)
A61K 31/4468 (2006.01)

(21) Application No: **2011298361** (22) Date of Filing: **2011.08.30**

(87) WIPO No: **WO12/028614**

(30) Priority Data

(31) Number
10174880.4 (32) Date
2010.09.01 (33) Country
EP

(43) Publication Date: **2012.03.08**
(44) Accepted Journal Date: **2014.03.13**

(71) Applicant(s)
Janssen Pharmaceutica NV

(72) Inventor(s)
Thuring, Johannes Wilhelmus John F.;Ver Donck, Luc August Laurentius

(74) Agent / Attorney
Shelston IP, L 21 60 Margaret St, Sydney, NSW, 2000

(56) Related Art
EP 0076530 A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2012 (08.03.2012)

(10) International Publication Number
WO 2012/028614 A1

(51) International Patent Classification:
C07D 211/58 (2006.01) A61K 31/4468 (2006.01)
A61P 11/00 (2006.01)

(21) International Application Number:
PCT/EP2011/064906

(22) International Filing Date:
30 August 2011 (30.08.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10174880.4 1 September 2010 (01.09.2010) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): THURING, Johannes, Wilhelmus, John F. [NL/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). VER DONCK, Luc, August, Laurentius [BE/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: JANSSEN PHARMACEUTICA NV; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: 5-HT_{2B} RECEPTOR ANTAGONISTS



(57) Abstract: The present invention relates to novel fluorinated piperidine derivatives having antagonistic activity at the 5-HT_{2B} receptor, pharmaceutical compositions comprising these compounds and their use as a medicine in the treatment or prevention of pulmonary arterial hypertension, pulmonary fibrosis or irritable bowel syndrome.

5-HT_{2B} RECEPTOR ANTAGONISTS

FIELD OF THE INVENTION

The present invention relates to novel fluorinated piperidine derivatives having antagonistic activity at the 5-HT_{2B} receptor, pharmaceutical compositions comprising these compounds and their use as a medicine.

BACKGROUND OF THE INVENTION


Cisapride is a serotonin 5-HT₄ receptor agonist useful as a gastropotokinetic drug.

It interacts significantly with several other receptors such as 5-HT_{2A} and 5-HT_{2C}; D_{2L}; 5-HT_{3A/B}; Alpha_{1A}, Alpha_{2A}, Alpha_{2B} and Alpha_{2C}. It was withdrawn from some markets in 2000 due to reports of sudden cardiac arrhythmias. At the origin of this side effect is drug-induced QT prolongation by blockade of the hERG potassium channel (human ether-a-go-go related gene). One of the known pharmacophores of a hERG channel blocker comprises a hydrophilic and a hydrophobic moiety linked by a middle part having a basic nitrogen atom. At physiological pH, the basic nitrogen is protonated and is involved in cation-π interaction with Tyr 652 residues within the hERG channel pore. In order to lower the pKa value of piperidine nitrogen atom, and thereby reduce the likelihood of blockade of the hERG channel, derivatives of cisapride were prepared wherein 3-methoxy-piperidine was replaced by 3-fluoropiperidine and 3,3-difluoropiperidine.

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

SUMMARY OF THE INVENTION

The present invention concerns a compound of formula (I)




or a stereochemically isomeric form thereof, wherein

R is hydrogen or fluoro, or
an addition salt or a solvate thereof.

Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

Illustrative of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described above. An illustration of the invention is a pharmaceutical composition made by mixing any of the



compounds described above and a pharmaceutically acceptable carrier. Illustrating the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier.

Exemplifying the invention are methods of treating a disorder mediated by the 5-HT_{2B} receptor, comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.

Further exemplifying the invention are methods of inhibiting the 5-HT_{2B} receptor, comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.

An example of the invention is a method of treating a disorder selected from the group consisting of pulmonary arterial hypertension, pulmonary fibrosis, irritable bowel syndrome, cardiovascular disorders such as chronic heart disease, congestive heart failure and hypertension, comprising administering to a subject in need thereof, a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.

Another example of the invention is any of the compounds described above for use in treating pulmonary arterial hypertension, pulmonary fibrosis, irritable bowel syndrome, cardiovascular disorders such as chronic heart disease, congestive heart failure and hypertension, in a subject in need thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds of formula (I) as defined hereinbefore, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are selective antagonists at the 5-HT_{2B} receptor.

In an embodiment of the present invention, R is fluoro and the compound is a racemic mixture or an addition salt or a solvate thereof.

In another embodiment of the present invention, R is fluoro and the compound has an optical rotation $[\alpha] = +14.1^\circ$ (c=0.3, MeOH, $\lambda = 598$ nm; 20°C), or an addition salt or a solvate thereof.

In another embodiment of the present invention, R is fluoro and the compound has an optical rotation $[\alpha] = -14.4^\circ$ (c=0.3, MeOH, $\lambda = 598$ nm; 20°C), or an addition salt or a solvate thereof.

In another embodiment of the present invention, R is hydrogen and the substituents in position 3 and 4 of the piperidine moiety have a cis orientation, or an addition salt or a solvate thereof.

5 In another embodiment of the present invention, R is hydrogen, the substituents in position 3 and 4 of the piperidine moiety have a cis orientation and the compound has an optical rotation $[\alpha] = +39.8^\circ$ (c=0.2, MeOH, $\lambda = 598$ nm; 20°C), or an addition salt or a solvate thereof.

10 In another embodiment of the present invention, R is hydrogen, the substituents in position 3 and 4 of the piperidine moiety have a cis orientation and the compound has an optical rotation $[\alpha] = -45.5^\circ$ (c=0.2, MeOH, $\lambda = 598$ nm; 20°C), or an addition salt or a solvate thereof.

In another embodiment of the present invention, R is hydrogen and the substituents in position 3 and 4 of the piperidine moiety have a trans orientation, or an addition salt or a solvate thereof.

15 In another embodiment of the present invention, R is hydrogen, the substituents in position 3 and 4 of the piperidine moiety have a trans orientation and the compound has an optical rotation $[\alpha] = +19.2^\circ$ (c=0.4, MeOH, $\lambda = 598$ nm; 20°C), or an addition salt or a solvate thereof.

20 In another embodiment of the present invention, R is hydrogen, the substituents in position 3 and 4 of the piperidine moiety have a trans orientation and the compound has an optical rotation $[\alpha] = -22.8^\circ$ (c=0.3, MeOH, $\lambda = 598$ nm; 20°C), or an addition salt or a solvate thereof.

25 As anticipated, the fluorinated cisapride derivatives are significantly less potent hERG channel blockers than cisapride and thus much less likely to cause drug-induced QT prolongation. Unexpectedly though, the receptor affinities change in various ways so as to yield compounds with a more selective profile. Affinities for 5-HT_{2A} and D_{2L} receptors diminish significantly, and for 5-HT_{3A/B}, 5-HT_{4B}, Alpha_{1A}, Alpha_{2A}, Alpha_{2B} and Alpha_{2C} receptors they show a trend to a reduction. The only exception is the affinity for the 5-HT_{2B} receptor which increases significantly.

30 5-HT_{2B} receptor antagonists are indicated for the treatment or the prevention of pulmonary arterial hypertension, pulmonary fibrosis or irritable bowel syndrome. Pulmonary arterial hypertension may be idiopathic, familial, or associated with other diseases such as HIV infection, or use of certain drugs. It may also be associated with heart or lung diseases such as chronic obstructive pulmonary disease (COPD),

interstitial lung disease or chronic exposure to high altitude. Pulmonary fibrosis is characterized by chronic inflammation and progressive fibrosis of the alveolar walls, with steadily progressing dyspnea, resulting finally in death from oxygen lack or right heart failure. Irritable bowel syndrome is a chronic noninflammatory disease

5 characterized by abdominal pain, altered bowel habits consisting of diarrhea or constipation or both, and no pathological change. It is a common disorder with a psychophysiological basis. The 5-HT_{2B} receptor antagonists may also be used to treat cardiovascular disorders such as chronic heart disease, congestive heart failure and hypertension.

10

DEFINITIONS

The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who is or has been the object of treatment, observation or experiment.

15 The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

20 As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

25 It will be appreciated that some of the compounds according to formula (I) and the addition salts, hydrates and solvates thereof may contain one or more centers of chirality and exist as stereoisomeric forms.

30 The term "stereoisomeric forms" as used hereinbefore or hereinafter defines all the possible stereoisomeric forms which the compounds according to formula (I) and their addition salts may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms according to formula (I) and their salts, solvates, substantially free, *i.e.* associated with less than 10%, preferably less than 5%, in particular less than 2% and most 35 preferably less than 1% of the other isomers.

Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the

5 scope of the present invention. Preferably, wherein the compound is present as an enantiomer, the enantiomer is present at an enantiomeric excess of greater than or equal to about 80%, more preferably, at an enantiomeric excess of greater than or equal to about 90%, more preferably still, at an enantiomeric excess of greater than or equal to about 95%, more preferably still, at an enantiomeric excess of greater than or equal to

10 about 98%, most preferably, at an enantiomeric excess of greater than or equal to about 99%. Similarly, wherein the compound is present as a diastereomer, the diastereomer is present at an diastereomeric excess of greater than or equal to about 80%, more preferably, at an diastereomeric excess of greater than or equal to about 90%, more preferably still, at an diastereomeric excess of greater than or equal to about 95%, more

15 preferably still, at an diastereomeric excess of greater than or equal to about 98%, most preferably, at an diastereomeric excess of greater than or equal to about 99%.

Furthermore, some of the crystalline forms for the compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the present invention may

20 form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts". Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the

25 compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.

Representative acids which may be used in the preparation of pharmaceutically acceptable salts include, but are not limited to, the following: acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic

acid, benzenesulfonic acid, benzoic acid, 4- acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid,

5 glucoheptonic acid, D-gluconic acid, D-glucoronic acid, L-glutamic acid, beta-oxo-glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, (+)-L-lactic acid, (±)-DL-lactic acid, lactobionic acid, maleic acid, (-)-L-malic acid, malonic acid, (±)-DL-mandelic acid, meglumine, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5- disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid,

10 nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L- pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoromethylsulfonic acid, and undecylenic acid.

15 Some of the compounds according to formula (I) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

PHARMACEUTICAL COMPOSITIONS

20 The present invention also provides compositions for preventing or treating diseases in which inhibition of pulmonary arterial hypertension or pulmonary fibrosis is beneficial.

25 Said compositions comprising a therapeutically effective amount of a compound according to formula (I) and a pharmaceutically acceptable carrier or diluent.

30 While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition comprising a compound according to the present invention, together with a pharmaceutically acceptable carrier or diluent. The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.

35 The pharmaceutical compositions of this invention may be prepared by any methods well known in the art of pharmacy. A therapeutically effective amount of the particular compound, in base form or addition salt form, as the active ingredient is

combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous or 5 parenteral administration; or topical administration such as inhalation or insufflation. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, 10 binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid 15 solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises 20 a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, 25 as a spot-on or as an ointment.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity 30 of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, suppositories, wafers, injectable solutions or suspensions, powders for inhalation, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

35 The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the

condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the
5 treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.

Depending on the mode of administration, the pharmaceutical composition will comprise from 0.05 to 99 % by weight, preferably from 0.1 to 70 % by weight, more preferably from 0.1 to 50 % by weight of the active ingredient, and, from 1 to 99.95 %
10 by weight, preferably from 30 to 99.9 % by weight, more preferably from 50 to 99.9 % by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.

The present compounds can be used for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via
15 inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. The compounds are preferably orally administered. The exact dosage and frequency of administration depends on the particular compound according to formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient
20 as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.

The amount of a compound of Formula (I) that can be combined with a carrier
25 material to produce a single dosage form will vary depending upon the disease treated, the mammalian species, and the particular mode of administration. However, as a general guide, suitable unit doses for the compounds of the present invention can, for example, preferably contain between 0.1 mg to about 1000 mg of the active compound. A preferred unit dose is between 1 mg to about 500 mg. A more preferred unit dose is
30 between 1 mg to about 300 mg. Even more preferred unit dose is between 1 mg to about 100 mg. Such unit doses can be administered more than once a day, for example, 2, 3, 4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total dosage for a 70 kg adult is in the range of 0.001 to about 15 mg per kg weight of subject per administration. A preferred dosage is 0.01 to about 1.5 mg per kg weight of subject per
35 administration, and such therapy can extend for a number of weeks or months, and in some cases, years. It will be understood, however, that the specific dose level for any

particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs that have previously been administered; and the severity of the particular 5 disease undergoing therapy, as is well understood by those of skill in the area.

A typical dosage can be one 1 mg to about 100 mg tablet or 1 mg to about 300 mg taken once a day, or, multiple times per day, or one time-release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient. The time-release effect can be obtained by capsule materials that dissolve at different 10 pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release.

It can be necessary to use dosages outside these ranges in some cases as will be apparent to those skilled in the art. Further, it is noted that the clinician or treating physician will know how and when to start, interrupt, adjust, or terminate therapy in 15 conjunction with individual patient response.


The following examples are intended to illustrate but not to limit the scope of the present invention.

20 Experimental Part

Synthetic examples

Hereinafter, the term ‘m.p.’ means melting point, ‘THF’ means tetrahydrofuran, ‘DMF’ means dimethylformamide, ‘DCM’ means dichloromethane, ‘EtOAc’ means 25 ethylacetate, ‘AcOH’ means acetic acid, ‘MeOH’ means methanol, ‘rac’ means racemic, ‘Et₂O’ means diethylether, ‘DMAP’ means dimethylaminopyridine, ‘DMSO’ means dimethylsulfoxide, ‘hex’ means hexanes and ‘TFA’ means trifluoroacetic acid, DEA means diethylamine.

Example 1 : Synthesis of *trans*-4-amino-5-chloro-N-{3-fluoro-1-[3-(4-fluorophenoxy)-propyl]-piperidin-4-yl}-2-methoxybenzamide 7.



5 Synthesis of *cis*-1-Boc-3-fluoro-4-hydroxypiperidine 3

To a solution of 0.5 g (2.30 mmol) of *N*-Boc-3-fluoro-4-piperidinone **2** (*J. Med. Chem.* **1999**, *42*, 2087-2104) in 10 mL of dry THF was added dropwise 2.8 mL (2.76 mmol) of a 1M solution of Li-selectride in THF under N₂-atmosphere at 0°C. The solution was stirred at 0°C for 4 h, then 10 mL of NaOH 2M was added at 0°C and the mixture was stirred overnight at rt. The reaction mixture was extracted with Et₂O, dried over MgSO₄, filtered and evaporated under reduced pressure. The crude mixture was subjected to flash silicagel chromatography (hex/EtOAc/Et₃N 1:1:0.1) to yield 0.27 g (56%) of pure *cis*-1-Boc-3-fluoro-4-hydroxypiperidine **3** as a colorless oil which solidified upon standing at -20°C (freezer). Mp 48°C. ¹H NMR (300 MHz, CDCl₃): δ 1.46 (9H, s, 3xCH₃), 1.67-1.91 (2H, m, CH₂), 2.40-2.65 (1H, m, OH), 2.92-3.35 (2H, m, CH₂CH_aH_bN and CH_aH_bCHF), 3.55-3.94 (3H, m, CH₂CH_aH_bN and CHO and CH_aH_bCHF), 4.52 (1H, dm, J = 48.4 Hz, CHF). ¹⁹F NMR (282 MHz, CDCl₃): δ -201.9 and -203.1 (1F, 2 x m). ¹³C NMR (75 MHz, CDCl₃): δ 28.4 (3x), 29.2, 40.4, 44.8, 68.0 (d, J = 17.3 Hz), 80.2, 88.6 (d, J = 177.7 Hz), 155.1. IR (KBr): ν 3413, 1674, 1429, 1167 cm⁻¹. GC-MS (EI): m/z (%): 219 (M⁺, 4), 164 (46), 146 (50), 57 (C₄H₉⁺, 100).

Synthesis of *trans*-4-azido-1-Boc-3-fluoropiperidine 4

To a solution of 0.60 g (2.74 mmol) of *cis*-1-Boc-3-fluoro-4-hydroxypiperidine **3** in 15 mL DCM was added 0.42 g (4.11 mmol) of triethylamine and 37 mg (0.3 mmol) of 4-(*N,N*-dimethylamino)pyridine (DMAP) at rt. Then a solution of 0.57 g (3.01 mmol) of 5 *p*-toluenesulfonyl chloride in 2 mL of DCM was added under a dry atmosphere (CaCl₂-tube) at rt. After stirring for 15h at rt, the solution was poured in brine (20 mL) and extracted with DCM (3x 25 mL). After drying over MgSO₄, filtration and evaporation of the solvent, the crude mixture was used as such in the next step without further purification. The obtained tosylate was dissolved in 5 mL of dry DMSO and 0.36 g 10 (5.48 mmol) of NaN₃ was added. The mixture was stirred under N₂-atmosphere at 90°C for 15h. After cooling, the mixture was poured in brine (10 mL) and extracted with EtOAc. The combined extract were washed with brine, dried over MgSO₄, filtered and evaporated in vacuo. *trans*-4-Azido-1-Boc-3-fluoropiperidine **4** was obtained as a colorless oil in 92% yield from 4-hydroxypiperidine **3** and was sufficiently pure for 15 further use. ¹H NMR (CDCl₃): δ 1.43 (9H, s); 1.44-1.64 (1H, m); 1.97 (1H, ddd, J = 4.3 Hz, 8.4 Hz, 18.0 Hz); 2.99 (1H, ddd, J = 3.3 Hz, 10.5 Hz, 13.8 Hz); 3.00-3.15 (2H, m); 3.57-3.68 (1H, m); 3.79 (1H, dt, J = 13.8 Hz, J = 4.4 Hz); 4.00-4.19 (1H, m); 4.33 (tdd, J = 47.9 Hz, J = 8.3 Hz, J = 4.4 Hz). ¹⁹F NMR (CDCl₃): δ -188.1 (1F, d(br), J = 47.4 Hz). ¹³C NMR (CDCl₃): δ 28.3 (4x), 41.2 (br), 45.5 (br), 61.4 (d, J = 20.7 Hz), 80.6, 20 88.9 (d, J = 182.3 Hz), 154.4. IR (ATR, cm⁻¹): ν = 2099, 1693, 1417, 1236, 1161, 1141. MS (ES+) *m/z* (%): 227 (M+H⁺, 100).

Synthesis of *trans*-4-amino-1-Boc-3-fluoropiperidine 5

To a solution of 0.59 g (2.42 mmol) of *trans*-4-azido-1-Boc-3-fluoropiperidine **4** in 10 mL of MeOH was added 0.61 g (9.67 mmol) of ammonium formate and 0.25 g (0.24 mmol Pd) of 10% Pd on carbon. The reaction mixture was stirred under N₂-atmosphere at 50°C for 5h. After cooling, the mixture was filtered over diatomaceous earth and evaporated under reduced pressure. The crude mixture was then subjected to flash silicagel chromatography (5% Et₃N in EtOAc, short path column) to give 0.42 g (80%) 25 of *trans*-4-amino-1-Boc-3-fluoropiperidine **5** as an oil. ¹H NMR (CDCl₃): δ 1.39 (9H, s); 1.60 (2H, s(br)); 1.76-1.86 (1H, m); 2.65-2.76 (2H, m); 2.78-2.90 (2H, m); 3.89-3.97 (1H, m); 4.01 (1H, dm, J = 48.5 Hz); 4.15-4.30 (1H, m). ¹⁹F NMR (CDCl₃): δ -191.0 to -190.3 (1F, m). ¹³C NMR (CDCl₃): δ 28.4 (3x), 31.8, 41.9 (br), 46.2 (br), 53.5 (d, J = 18.5 Hz), 80.3, 93.0 (d, J = 177.7 Hz), 154.6. IR (ATR, cm⁻¹): ν = 1685, 1415, 30 1244, 1152, 1028. MS (ES+) *m/z* (%): 204 (M-CH₃+H⁺), 163 (M-3CH₃+2H⁺, 100).

Synthesis of *trans*-tert-butyl 4-(4-amino-5-chloro-2-methoxybenzoylamino)-3-fluoropiperidine-1-carboxylate 6

To a solution of 0.41 g (2.02 mmol) of 4-amino-5-chloro-2-methoxybenzoic acid in 10 mL of dry DMF was added 0.29 g (2.89 mmol) of triethylamine at room temperature under N₂-atmosphere. After stirring for 10 min at rt, a solution of 0.22 g (2.02 mmol) of ethyl chloroformate in 2 mL of DMF was added dropwise at rt and stirring was continued for 30 min, while the temperature was maintained at rt (cooling with waterbath at rt). Then 0.27 g (2.02 mmol) of hydroxybenzotriazole was added as a solid in one portion at rt and the solution was stirred for 30 min. Subsequently, a solution of 0.42 g (1.93 mmol) of amine 5 in 3 mL of DMF was added dropwise at rt and the reaction mixture was stirred overnight at rt. Afterwards, the mixture was poured in 20 mL of brine and extracted with EtOAc (3x 25 mL). The combined organic fraction was washed with brine, dried over MgSO₄, filtered and evaporated under reduced pressure. The crude mixture was subjected to flash silicagel chromatography (hex/EtOAc/Et₃N 1:1:0.1) to yield 0.72 g (93%) of pure *trans*-tert-butyl 4-(4-amino-5-chloro-2-methoxybenzoylamino)-3-fluoropiperidine-1-carboxylate 6 as a solid. ¹H NMR (CDCl₃): δ 1.47 (9H, s); 2.17-2.28 (1H, m); 2.96-3.19 (2H, m); 3.74 (1H, dm, J = 13.7 Hz); 3.90 (3H, s); 3.92-4.40 (3H, m); 4.45 (1H, ddt, J = 4.4 Hz, 8.3 Hz, J = 48.4 Hz); 6.30 (1H, s); 7.82 (1H, d, J = 7.2 Hz); 8.08 (1H, s). ¹⁹F NMR (CDCl₃): δ -189.0 (d, J = 44.7 Hz). ¹³C NMR (CDCl₃): δ 28.4 (3x), 29.1 (br), 41.5 (br), 45.6 (br), 50.1 (br), 56.4, 80.4, 88.2 (d, J = 182.3 Hz), 97.9, 111.8, 112.1, 133.2, 147.1, 154.7, 157.6; 164.5. IR (ATR, cm⁻¹): ν = 3478, 3378, 1683, 1619, 1593, 1420, 1247, 1146. MS (ES+) *m/z* (%): 346/48 (M+H⁺, 100); 402/404 (M+H⁺, 60).

25 Synthesis of *trans*-4-amino-5-chloro-N-{3-fluoro-1-[3-(4-fluorophenoxy)propyl]-piperidin-4-yl}-2-methoxybenzamide 7

To a solution of 0.14 g (0.34 mmol) of tert-butyl 4-(4-amino-5-chloro-2-methoxybenzoylamino)-3-fluoropiperidine-1-carboxylate 6 in 5 mL of DCM was added 0.39 g (3.4 mmol) of trifluoroacetic acid at 0°C under dry atmosphere (CaCl₂-tube). After stirring for 5 h at 0°C, the mixture was evaporated under reduced pressure. The oily residue was taken up in 10 mL of dry diethyl ether, cooled to 0°C and the formed crystalline TFA salt was isolated (filter or decant Et₂O). After drying and further evaporation the white crystalline TFA-salt of 4-amino-5-chloro-N-(3-fluoropiperidin-4-yl)-2-methoxybenzamide was dissolved in 5 mL of dry DMF. To the solution was added 0.17 g (1.70 mmol) of triethylamine, 55 mg (0.34 mmol) of sodium iodide and then 65 mg (0.34 mmol) of 3-(4-fluorophenoxy)propyl-1-chloride at rt under dry atmosphere. The mixture heated to 110° to 120°C during 4h. After cooling, the

mixture was diluted with 25 mL of EtOAc, poured in brine (25 mL) and extracted with EtOAc (3x 25 mL). The combined organic phase was washed with brine, dried over MgSO₄, filtered and evaporated under reduced pressure. The crude mixture was subjected to gradient flash silicagel chromatography (EtOAc/hex/Et₃N 3:2:0.1 to 1% Et₃N in EtOAc) to give 85 mg (55%) of *trans*-4-amino-5-chloro-*N*-(3-fluoro-1-[3-(4-fluorophenoxy)propyl]piperidin-4-yl)-2-methoxybenzamide 7 as a pale yellow solid. Mp 125°C. Optional recrystallization from EtOAc/EtOH. ¹H NMR (CDCl₃): δ 1.46-1.59 (1H, m); 1.94 (2H, quint, J = 6.6 Hz); 2.18-2.34 (3H, m); 2.58 (2H, t, J = 6.6 Hz); 2.76 (1H, dm, J = 11.6 Hz); 3.13 (1H, td(br), J = 4.4 Hz, 9.9 Hz); 3.87 (3H, s); 3.96 (2H, t, J = 6.6 Hz); 4.09-4.23 (1H, m); 4.47 (1H, ddt, J = 4.4 Hz, J = 9.4 Hz, J = 49.5 Hz); 4.48 (2H, s(br)); 6.02 (1H, s); 6.79-6.86 (2H, m); 6.92-7.00 (2H, m); 7.79 (1H, d, J = 7.7 Hz), 8.09 (1H, s). ¹⁹F NMR (CDCl₃): δ -187.6 (d, J = 51.3 Hz); -124.0 (tt, J = 3.9 Hz, J = 9.2 Hz). ¹³C NMR (CDCl₃): δ 27.0, 29.9 (d, J = 6.9 Hz), 51.0 (d, J = 18.5 Hz), 51.5, 54.6, 56.2, 56.3 (d, J = 24.2 Hz), 66.7, 89.0, 90.2 (d, J = 178.8 Hz), 97.9, 111.7, 112.3, 2 x 115.5 (d, J = 8.0 Hz), 2 x 115.8 (d, J = 23.0 Hz), 133.2, 147.0, 155.2, 157.3 (d, J = 238.9 Hz), 157.6, 164.6. IR (ATR, cm⁻¹): ν = 3453, 3370, 3317, 3194, 1631, 1584, 1537, 1508, 1250, 1200. MS (ES+) *m/z* (%): 454/456 (M+H⁺, 100).

Chiral separation of *trans*-4-amino-5-chloro-*N*-(3-fluoro-1-[3-(4-fluorophenoxy)-propyl]-piperidin-4-yl)-2-methoxybenzamide 7.

Compound 7 was resolved into its enantiomers by supercritical fluid chromatography.

Amount: 80 mg (Load: 10 mg/ 3.00 ml)
25 Conditions:


Column: OD 20x250mm (I)
Mobile Phase: 37% MeOH (with 0.2% iPrNH₂) hold 9.00 min
Parameters: Flow =50 ml/min
30 Column temperature =40 °C
Nozzle pressure = 10 MPa

Injection type: stacked injections (8 x)
Collection method: Collection using standard peak detection.
35

Peak 1 eluted at 5 min 20' and yielded the levorotatory enantiomer (-)-7
[α] = -22.8° (c=0.3, MeOH, λ = 598 nm; 20°C).

Peak 2 eluted at 7 min 30' and yielded the dextrorotatory enantiomer (+)-7
40 [α] = +19.2° (c=0.4, MeOH, λ = 598 nm; 20°C).

Example 2 : Synthesis of *cis*-4-amino-5-chloro-*N*-(3-fluoro-1-[3-(4-fluorophenoxy)-propyl]-piperidin-4-yl)-2-methoxybenzamide **12**.



5

Synthesis of *cis*-*N*-(1-Boc-3-fluoropiperidin-4-yl)amine **10**

The compound was prepared as disclosed in literature references:

- 1) *J. Med. Chem.* **1999**, *42*, 2087-2104, and
- 2) WO 2007071965.

10

Synthesis of *cis*-tert-butyl 4-(4-amino-5-chloro-2-methoxybenzoylamino)-3-fluoropiperidine-1-carboxylate **11**

To a solution of 0.97 g (4.82 mmol) of 4-amino-5-chloro-2-methoxybenzoic acid in 25 mL of dry DMF was added 0.70 g (6.88 mmol) of triethylamine at room temperature

under N_2 -atmosphere. After stirring for 10 min at rt, a solution of 0.52 g (4.82 mmol) of ethyl chloroformate in 1 mL of DMF was added dropwise at rt and stirring was continued for 30 min. Then 0.65 g (4.82 mmol) of hydroxybenzotriazole was added as a solid in one portion at rt and the solution was stirred for 30 min. Subsequently, a solution of 1.0 g (4.59 mmol) of amine **10** in 3 mL of DMF was added dropwise at rt and the reaction mixture was stirred overnight at rt. Afterwards, the mixture was poured

20

in 100 mL of brine and extracted with EtOAc (4x 30 mL). The combined organic fraction was washed with brine, dried over MgSO₄, filtered and evaporated under reduced pressure. The crude mixture was subjected to flash silicagel chromatography (hex/EtOAc/Et₃N 1:1:0.1; R_f = 0.01) to yield 1.25 g (68%) of pure tert-butyl 4-(4-amino-5-chloro-2-methoxybenzoylamino)-3-fluoropiperidine-1-carboxylate **11** as a solid. Mp 198-199°C. ¹H NMR (CDCl₃): δ 1.35 (9H, s); 1.44-1.77 (2H, m); 2.77-2.98 (1H, m); 3.81 (3H, s); 4.04-4.32 (4H, m); 4.42 (2H, s(br)); 4.65 (1H, d, J = 48.9 Hz); 6.23 (1H, s); 7.95 (1H, s(br)); 8.01 (1H, s). ¹⁹F NMR (CDCl₃): δ -203.5 to -204.5 (1F, m). ¹³C NMR (CDCl₃): δ 26.6, 28.5 (3x), 42.3 (br), 46.5 (br), 48.6 (d, J = 17.3 Hz), 52.2, 80.1, 87.9 (d, J = 176.5 Hz), 97.9, 111.6, 112.0, 133.1, 147.1, 155.2, 157.7, 164.0. IR (ATR, cm⁻¹): ν = 3470, 3393, 3310, 1697, 1637, 1612, 1534, 1420. MS (ES⁺) m/z (%): 402/404 (M+H⁺, 100).

Synthesis of *cis*-4-amino-5-chloro-N-{3-fluoro-1-[3-(4-fluorophenoxy)propyl]-piperidin-4-yl}-2-methoxybenzamide **12**.

To a solution of 1.00 g (2.49 mmol) of tert-butyl 4-(4-amino-5-chloro-2-methoxybenzoylamino)-3-fluoropiperidine-1-carboxylate **11** in 10 mL of DCM was added 2.83 g (24.9 mmol) of trifluoroacetic acid at 0°C under dry atmosphere (CaCl₂-tube). After stirring for 4 h at 0°C, the mixture was evaporated under reduced pressure. The oily residue was taken up in 25 mL of dry diethyl ether, cooled to 0°C and the formed crystalline TFA salt was isolated (filter or decant Et₂O). After drying and further evaporation in vacuo 0.78 g of the TFA-salt of 4-amino-5-chloro-N-(3-fluoropiperidin-4-yl)-2-methoxybenzamide was obtained as a white solid. To a solution of 0.78 g of the obtained salt in 10 mL of DMF was added 1.26 g (12.45 mmol) of triethyl amine, 0.37 g (2.49 mmol) of sodium iodide and then 0.47 g (2.49 mmol) of 3-(4-fluorophenoxy)propyl-1-chloride at rt under dry atmosphere. The mixture heated to 120°C for 2h. After cooling, the mixture was diluted with 25 mL of EtOAc, poured in brine (25 mL) and extracted with EtOAc (3x 25 mL). The combined organic phase was washed with brine, dried over MgSO₄, filtered and evaporated under reduced pressure. The crude mixture was subjected to gradient flash silicagel chromatography (EtOAc/hex/Et₃N 3:1:0.1 to 1% Et₃N in EtOAc) to give 49% of 4-amino-5-chloro-N-{3-fluoro-1-[3-(4-fluorophenoxy)propyl]piperidin-4-yl}-2-methoxybenzamide **12** as a pale yellow solid. Mp 137°C. Optional recrystallization from EtOAc/EtOH. ¹H NMR (CDCl₃): δ 1.83-1.92 (2H, m); 1.94 (2H, quint, J = 6.6 Hz); 2.10-2.35 (2H, m); 2.47-2.61 (2H, m); 2.94 (1H, d(br), J = 11.6 Hz); 3.24 (1H, t(br), J = 11.3 Hz); 3.85 (3H, s); 3.95 (2H, t, J = 6.6 Hz); 4.08-4.27 (1H, m); 4.41 (2H, s(br)); 4.73 (1H, d(br), J = 49.6 Hz); 6.26 (1H, s), 6.76-6.84 (2H, m); 6.89-6.97 (2H, m); 8.03 (1H, s(br)); 8.06 (1H, s).

¹⁹F NMR (CDCl₃): δ -199.3 to -200.0 (1F, m); -124.1 (1F, tt, J = 7.9 Hz, J = 5.3 Hz).
¹³C NMR (CDCl₃): δ 26.9, 27.4, 48.3 (d, J = 18.4 Hz), 52.0, 54.7, 56.1 (d, J = 18.3 Hz),
56.2, 66.8, 88.8 (d, J = 175.3 Hz), 97.9 Hz, 111.6, 112.2, 2 x 115.6 (d, J = 8.0 Hz), 2 x
115.8 (d, J = 23.1 Hz), 133.1, 147.0, 155.2, 157.2 (d, J = 237.7 Hz), 157.7, 164.0. IR
5 (ATR, cm⁻¹): ν = 3477, 3398, 3322, 1636, 1612, 1583, 1537, 1505, 1247, 1209. MS
(ES+) *m/z* (%): 454/456 (M+H⁺, 100).

Chiral separation of *cis*-4-amino-5-chloro-*N*-(3-fluoro-1-[3-(4-fluorophenoxy)propyl]-piperidin-4-yl)-2-methoxybenzamide 12.

10 Compound 12 was resolved into its enantiomers by supercritical fluid chromatography.

Amount: 152 mg (Load: 8.5 mg/ 1.250 ml)

Conditions:

15 *Column:* OJ 20x250mm (I)
Mobile Phase: 19% MeOH (with 0.2% iPrNH₂) hold 14.00 min
Parameters: Flow = 50 ml/min
20 Column temperature = 40 °C
Nozzle pressure = 10 MPa

Injection type: stacked injections (18 x)
Collection method: Collection using standard peak detection.

25 Peak 1 eluted at 10 min 20' and yielded the levorotatory enantiomer (-)-12
[α] = -45.5° (c=0.2, MeOH, λ = 598 nm; 20°C).

Peak 2 eluted at 11 min 40' and yielded the dextrorotatory enantiomer (+)-12
[α] = +39.8° (c=0.2, MeOH, λ = 598 nm; 20°C).

30 Example 3 : Synthesis of 4-amino-5-chloro-*N*-(3,3-difluoro-1-[3-(4-fluorophenoxy)-propyl]-piperidin-4-yl)-2-methoxybenzamide 17

Synthesis of benzyl-(3,3-difluoro-piperidin-4-yl)amine 14

35 In a 100 mL flask, 2.00 g (8.0 mmol) of 3,3-difluoro-4,4-dihydroxy-1-trifluoroacetyl piperidine 13 (J. Org Chem. 2010, 75, 929-932) and 2.15 g (20.0 mmol; 2.5 equiv) of benzylamine were dissolved in 50 mL of toluene. The mixture was heated under reflux with a Dean Stark trap during 15 hours. After cooling to room temperature, the solvent was removed in vacuo. The resulting oil was dissolved in 25


mL of absolute methanol and 0.56 g (8.8 mmol; 1.1 equiv) of sodium cyanoborohydride and 0.48 g (8.0 mmol; 1 equiv) of acetic acid were slowly added at room temperature. The solution was stirred during 4 hours at room temperature. After removing the solvent under vacuum, the crude oil was redissolved in 50 mL of dichloromethane and poured in 50 mL of a saturated aqueous NaHCO₃ solution and was subsequently extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine and dried over MgSO₄. Filtration of the solids and evaporation of the solvent resulted in a crude oil which was purified via flash chromatography (EtOAc, R_f = 0.03) yielding 1.32 g (5.8 mmol; 73% yield) of benzyl-(3,3-difluoro-piperidin-4-yl)amine **14** as a yellow oil.

¹H NMR (CDCl₃): δ 1.51 (1H, q, J = 11.8 Hz, CH_aH_b); 1.69 (1H, s(broad), NH); 1.94 (1H, d, J = 11.8 Hz, CH_aH_b); 2.58 (1H, t, J = 12.8 Hz, NCH_aH_b); 2.74 (1H, dd, J = 25.3 Hz, 14.3 Hz, NCH_aH_bCF₂); 2.86-2.97 (1H, m, NCH); 3.02 (1H, d, J = 12.8 Hz, NCH_aH_b); 3.22 (1H, dt, J = 14.3 Hz, 9.4 Hz, NCH_aH_bCF₂); 3.91 (1H, d, J = 14.9 Hz, CH_aH_bPh); 3.96 (1H, d, 14.9 Hz, CH_aH_bPh); 7.22-7.38 (5H, m, 5 × CH_{ar}). ¹⁹F NMR (CDCl₃): δ -109.0 (1F, d, J = 234.1 Hz); -120.4 (1F, d(broad), J = 234.1 Hz). ¹³C NMR (CDCl₃): δ 31.9 (CH₂); 43.3 (NCH₂); 50.5 (t, J = 27.1 Hz, NCH₂CF₂); 51.5 (NCH₂Ph); 57.1 (t, J = 20.8 Hz, NCH); 120.9 (t, J = 247.5 Hz, CF₂); 126.9 (CH_{ar}); 127.9 (2 × CH_{ar}); 128.3 (2 × CH_{ar}); 140.1 (C_{ar}). IR (ATR, cm⁻¹): ν = 3324 (NH); 3028; 2930; 2859; 1495; 1453; 1317; 1274; 1181; 1130; 1106; 1072; 983; 912; 855; 740; 699. MS (ES+) m/z (%): 227 (M+H⁺, 100).

Synthesis of benzyl-{3,3-difluoro-1-[3-(4-fluoro-phenoxy)propyl]piperidin-4-yl}amine **15**

In a 100 mL flask, a mixture of 1.22 g (5.4 mmol) of benzyl-(3,3-difluoro-piperidin-4-yl)amine **14**, 0.81 g (5.4 mmol; 1 equiv) of sodium iodide, 2.73 g (27.0 mmol; 5 equiv) of triethylamine and 1.05 g (5.4 mmol; 1 equiv) of 1-(3-chloropropoxy)-4-fluorobenzene in 70 mL was stirred at 120°C during 30 hours. Another portion of 2.73 g (27.0 mmol; 5 equiv) of triethylamine was added and the mixture stirred at 120°C during 16 hours. Then 1.05 g (5.4 mmol; 1 equiv) of 1-(3-chloropropoxy)-4-fluorobenzene was added and the mixture was stirred at 120°C during 54 hours until the reaction was completed. The solvent was removed under vacuum and the crude oil was redissolved in 100 mL of EtOAc and washed with brine and dried over MgSO₄. Filtration of the solids and evaporation of the solvent resulted in a crude oil which was purified via flash chromatography (hexane/EtOAc 1:1, R_f = 0.19-0.38) yielding 1.00 g (2.6 mmol; 49% yield) of benzyl-{3,3-difluoro-1-[3-(4-fluoro-phenoxy)propyl]piperidin-4-yl}amine **15** as a brown oil.

¹H NMR (CDCl₃): δ 1.48-1.62 (1H, m, CH_aH_b); 1.58 (1H, s(broad), NH); 1.80-1.92 (1H, m, CH_aH_b); 1.86 (2H, quintet, J = 6.9 Hz, CH₂); 2.09 (1H, t, J = 10.7 Hz, NCH_aH_b); 2.26 (1H, ddd, J = 23.8 Hz, 12.3 Hz, 3.4 Hz, NCH_aH_bCF₂); 2.41-2.57 (2H, m, NCH₂); 2.68-2.82 (2H, m, NCH and NCH_aH_b); 2.99 (1H, td, J = 11.3 Hz, 8.8 Hz, NCH_aH_bCF₂); 3.84 (1H, d, J = 14.0 Hz, CH_aH_bPh); 3.89 (2H, t, J = 6.9 Hz, OCH₂); 3.91 (1H, d, 14.0 Hz, CH_aH_bPh); 6.74 (2H, dd, J = 9.4 Hz, 4.4 Hz, 2 × CH_{ar}); 6.87 (2H, t, J = 9.4 Hz, 2 × CH_{ar}); 7.14-7.30 (5H, m, 5 × CH_{ar}). ¹⁹F NMR (CDCl₃): δ -104.9 (1F, d, J = 225.6 Hz, CF_aF_b); -116.9 (1F, d(broad), J = 225.6 Hz, CF_aF_b); -124.0 (1F, tt, J = 7.9 Hz, 4.0 Hz, C_{ar}F). ¹³C NMR (CDCl₃): δ 26.7 (CH₂, alkyl); 29.2 (d, J = 5.8 Hz, CH₂); 50.8 (NCH₂); 51.5 (NCH₂Ph); 53.9 (NCH₂, alkyl); 57.0 (t, J = 20.8 Hz, NCH); 57.2 (t, J = 27.7 Hz, NCH₂CF₂); 66.4 (OCH₂); 115.4 (d, J = 8.1 Hz, 2 × CH_{ar}); 115.7 (d, J = 23.1 Hz, 2 × CH_{ar}); 120.9 (t, J = 245.2 Hz, CF₂); 127.0 (CH_{ar}); 128.0 (2 × CH_{ar}); 128.5 (2 × CH_{ar}); 140.2 (C_{ar}); 155.0 (d, J = 2.3 Hz, OC_{ar}); 157.1 (d, J = 238.8 Hz, C_{ar}F). IR (ATR, cm⁻¹): ν = 3334 (NH); 3062; 3028; 2953; 2823; 1682; 1602; 1505; 1470; 1454; 1388; 1346; 1292; 1247; 1205; 1152; 1118; 1097; 1064; 1028; 987; 912; 828; 736; 699. MS (ES+) *m/z* (%): 379 (M+H⁺, 100).



Synthesis of 3,3-difluoro-1-[3-(4-fluorophenoxy)propyl]piperidin-4-amine 16

In a dry pressure vessel, 0.83 g (2.2 mmol) of benzyl-{3,3-difluoro-1-[3-(4-fluorophenoxy)propyl]piperidin-4-yl}amine **15** was dissolved in 10 mL of methanol. After adding 0.33 g (40wt%) of Pd/C (10%) at 0°C, the mixture was stirred during 15 hours

5 at room temperature under hydrogen pressure of 480 kPa. The mixture was filtered over diatomaceous earth. The solvent was evaporated in vacuo to yield 0.57 g (2.0 mmol; 90% yield) of 3,3-difluoro-1-[3-(4-fluorophenoxy)propyl]piperidin-4-amine **16** as a yellow oil.

¹H NMR (CDCl₃): δ 1.54 (1H, dddd, J = 24.5 Hz, 11.3 Hz, 3.7 Hz, 1.7 Hz, CH_aH_b);

10 1.80-1.99 (1H, m, CH_aH_b); 1.86 (2H, quintet, J = 6.7 Hz, CH₂); 2.11 (1H, t, J = 11.6 Hz, NCH_aH_b); 2.21 (1H, ddd, J = 26.4 Hz, 12.1 Hz, 2.2 Hz, NCH_aH_bCF₂); 1.42 (2H, s(broad), NH₂); 2.44-2.61 (2H, m, NCH₂); 2.76-2.92 (2H, m, NCH and NCH_aH_b); 3.00-3.13 (1H, m, NCH_aH_bCF₂); 3.90 (2H, t, J = 6.7 Hz, OCH₂); 6.75 (2H, dd, J = 9.4 Hz, 4.4 Hz, 2 × CH_{ar}); 6.88 (2H, t, J = 9.4 Hz, 2 × CH_{ar}). ¹⁹F NMR (CDCl₃): δ -109.6 (1F, d, J = 239.4 Hz, CF_aF_b); -120.5 (1F, d(broad), J = 239.4 Hz, CF_aF_b); -124.0 (1F, tt, J = 7.9 Hz, 4.0 Hz, C_{ar}F). ¹³C NMR (CDCl₃): δ 26.8 (CH₂, alkyl); 30.6 (d, J = 6.9 Hz, CH₂); 51.4 (NCH₂); 52.8 (t, J = 22.5 Hz, NCH); 53.9 (NCH₂, alkyl); 57.0 (dd, J = 29.4 Hz, 24.8 Hz, NCH₂CF₂); 66.4 (OCH₂); 115.4 (d, J = 6.9 Hz, 2 × CH_{ar}); 115.7 (d, J = 21.9 Hz, 2 × CH_{ar}); 119.6 (dd, J = 245.8 Hz, 241.1 Hz, CF₂); 155.0 (OC_{ar}); 157.2 (d, J = 237.7 Hz, C_{ar}F). IR (ATR, cm⁻¹): ν = 3384; 2952; 2821; 1601; 1505; 1470; 1390; 1348; 1294; 1247; 1204; 1146; 1078; 915; 828; 757; 735. MS (ES+) *m/z* (%): 289 (M+H⁺, 100).

Synthesis of 4-amino-5-chloro-N-{3,3-difluoro-1-[3-(4-fluorophenoxy)propyl]-piperidin-4-yl}-2-methoxybenzamide 17

25 In a dry 50 mL flask, 0.44 g (2.2 mmol; 1.1 equiv) of 4-amino-5-chloro-2-

methoxybenzoic acid and 0.30 g (3 mmol; 1.5 equiv) of triethylamine were dissolved in 25 mL of dimethylformamide and stirred during 10 minutes at room temperature. Then the mixture was cooled to 0°C and 0.24 g (2.2 mmol; 1.1 equiv) of ethyl chloroformate was added and stirred during 30 minutes at room temperature. Then 0.29 g (2.2 mmol;

30 1.1 equiv) of 1-hydroxybenzotriazole was added and stirred during 30 minutes at room temperature. Then 0.57 g of 3,3-difluoro-1-[3-(4-fluorophenoxy)propyl]piperidin-4-amine **16** was added and the mixture was stirred at room temperature during 15 hours.

After evaporation of the solvent in vacuo, the crude oil was redissolved in EtOAc and poured in 50 mL of brine and extracted with EtOAc (4 × 50 mL). The organic phases were washed with brine and dried over MgSO₄. After filtration of the solids and evaporation of the solvent under vacuum, the crude oil was purified via flash chromatography (hexane/EtOAc 3:7, R_f = 0.35) yielding 0.66 g (1.4 mmol; 71% yield)

of pure 4-amino-5-chloro-*N*-{3,3-difluoro-1-[3-(4-fluorophenoxy)propyl]piperidin-4-yl}-2-methoxybenzamide **17** as white crystals. M.p. = 125.8 °C (hexane/EtOH 1:1).
¹H NMR (CDCl₃): δ 1.70 (1H, ddd, J = 24.8 Hz, 12.7 Hz, 3.9 Hz, CH_aH_b); 1.93 (2H, quintet, J = 6.6 Hz, CH₂); 2.01-2.12 (1H, m, CH_aH_b); 2.21 (1H, t, J = 11.8 Hz, 5 NCH_aH_b); 2.34 (1H, ddd, J = 28.8 Hz, 11.3 Hz, 1.7 Hz, NCH_aH_bCF₂); 2.50-2.69 (2H, m, NCH₂); 2.92 (1H, d, J = 11.8 Hz, NCH_aH_b); 3.19 (1H, td, J = 11.3 Hz, 4.4 Hz, NCH_aH_bCF₂); 3.86 (3H, s, OCH₃); 3.96 (2H, t, J = 6.6 Hz, OCH₂); 4.43 (3H, s(broad), NCH and NH₂); 6.26 (1H, s, CH_{ar}); 6.81 (2H, dd, J = 8.8 Hz, 4.4 Hz, 2 × CH_{ar}); 6.94 (2H, t, J = 8.8 Hz, 2 × CH_{ar}); 8.03 (1H, s(broad), NH); 8.06 (1H, s, CH_{ar}). ¹⁹F NMR (CDCl₃): δ -107.6 (1F, d, J = 240.7 Hz, CF_aF_b); -116.9 (1F, d(broad), J = 240.7 Hz, CF_aF_b); -124.0 (1F, tt, J = 7.9 Hz, 4.0 Hz, C_{ar}F). ¹³C NMR (CDCl₃): δ 26.8 (CH₂, alkyl); 29.6 (d, J = 5.8 Hz, CH₂); 50.2 (t, J = 19.6 Hz, NCH); 51.5 (NCH₂); 53.9 (NCH₂, alkyl); 56.2 (OCH₃); 58.0 (dd, J = 29.4 Hz, 23.7 Hz, NCH₂CF₂); 66.3 (OCH₂); 97.8 (CH_{ar}); 111.6 (C_{ar}CO); 111.9 (C_{ar}Cl); 115.4 (d, J = 8.1 Hz, 2 × CH_{ar}); 115.7 (d, J = 23.1 Hz, 2 × CH_{ar}); 118.9 (t, J = 245.8 Hz, CF₂); 133.1 (CH_{ar}); 147.1 (C_{ar}NH₂); 155.0 (d, J = 2.3 Hz, OC_{ar}); 157.2 (d, J = 237.7 Hz, C_{ar}F); 157.6 (C_{ar}OMe); 164.4 (C=O). IR (ATR, cm⁻¹): ν = 3480; 3398; 3329; 3194; 2964; 2886; 2818; 1641; 1614; 1584; 1538; 1506; 1462; 1318; 1247; 1208; 1146; 1124; 1074; 1037; 982; 910; 822; 753; 681. MS (ES+) *m/z* (%): 472/474 (M+H⁺, 100).

20

Chiral separation of 4-amino-5-chloro-*N*-{3,3-difluoro-1-[3-(4-fluorophenoxy)propyl]piperidin-4-yl}-2-methoxybenzamide **17**

170 mg of **17** was resolved into its enantiomers by supercritical fluid chromatography on a Berger Multigram™ SFC (Mettler, Toledo Co., Ltd) with an IC 250 mm*50mm, 25 5mm column.

Mobile phase : supercritical CO₂ : MeOH with 0.05% DEA = 75:25 at 160 ml/min

Column temperature : 38°C

Nozzle pressure : 30 MPa

Nozzle temperature : 60°C

30 Evaporator temperature : 20°C

Trimmer temperature : 25°C

Wavelength : 220 nm.

Peak 1 eluted at 7.4 min and yielded the dextrorotatory enantiomer (+)-**17**

35 e.e.% = 100% ; [α] = +14.1° (c=0.3, MeOH, λ = 598 nm; 20°C).

Peak 2 eluted at 8.5 min and yielded the levorotatory enantiomer (-)-**17**

e.e.% = 98.6 % ; $[\alpha] = -14.4^\circ$ (c=0.3, MeOH, $\lambda = 598$ nm; 20°C).

Pharmacological examples

5 Example 4 : Receptor binding

Competitive radioligand binding assays were used to determine the affinity of the test compounds for a particular receptor. Various concentrations of the non-labelled test compound were added to the incubation mixture with the membrane fraction, containing the receptor of interest, and a fixed low concentration (nM) of the 10 radioligand. During the incubation the radioligand bound to the receptor, but this was inhibited by the non-labelled test compound in proportion to its binding affinity and concentration.

Cell lines were established that stably express the human variant of the receptor under investigation after transfection with the appropriate cDNA (Table 1). Transfected cells 15 were grown under standard culture conditions, and membrane fractions were obtained upon centrifugation and homogenisation of the cells. Optimal membrane dilutions for binding studies were determined and aliquots were stored at -70°C until use. In a 96-well plate format, the appropriate radioligand was added to the membrane preparation containing the receptor under investigation. Compound solutions were prepared in 20 DMSO, and diluted 100-fold into the multiwell plate to a final test concentration of 10⁻⁹ to 10⁻⁵ M. After incubation with the test compound, the unbound radioligand was removed by filtration on G/F filters with a Filtermate 96. Microscint™ was added to the washed filter plates and the radioactivity bound to the receptor was measured by liquid scintillation counting in a TopCount (Packard). To measure the Non-Specific 25 Binding (NSB), a high concentration of the non-radiolabeled ligand was added to wells containing the membrane fraction and the radioligand.

Table 1: Summary of assay conditions for inhibition of radioligand binding to the receptors evaluated.

30

Receptor	Cell line	Radioligand	Conc. (nM)	Kd (nM)
5HT _{1A}	HEK293	3H-8-OH-DPAT	0.5	0.557
5HT _{2A}	NIH3T3	3H-ketanserin	2	0.628
5HT _{2B}	CHO	3H-5-HT	4	2.312
5HT _{2C}	CHO	3H-mesulergin	1	1.909
5HT _{3A/B}	HEK293	3H-GR65630	0.5	0.247
5HT _{4B}	HEK293	3H-GR113808	0.1	0.059

Receptor	Cell line	Radioligand	Conc. (nM)	Kd (nM)
Alpha _{1A}	CHO	3H-prazosin	0.25	0.226
Alpha _{2A}	CHO	3H-rauwolscine	1	0.485
Alpha _{2B}	CHO	3H-rauwolscine	1	0.853
Alpha _{2C}	CHO	3H-rauwolscine	1	0.100
D _{2L}	CHO	3H-spiperone	0.2	0.239
hERG	HEK293	3H-dofetilide	5	3.66

The % inhibition of binding of the radioligand to the receptor induced by the test compound was calculated by the formula %Effect = 100-[(sample-NSB) / (HC-NSB) * 100], where sample = radioactive count in a drug treated well, HC = radioactive count in control wells incubated with radioligand only. Using in house developed software, a best-fit curve was fitted by a minimum sum of squares method to the plot of % inhibition vs. concentration of the test compound. From this, the pIC₅₀ value (inhibitory concentration causing 50 % displacement of specific binding) was determined, as well as an estimate of the slope of the plot (Hill coefficient).

10

Table 2 : pIC₅₀ values

Co.No. Target	Ref.	(±)-17	(+)-17	(-)-17	(±)-7	(+)-7	(-)-7	(±)-12	(+)-12	(-)-12	trend
5HT _{1A}	5.71	5.1	5.25	<5	5.74	6.17	5.96	5.38	6.13	5.73	=
5HT _{2A}	7.84	5.71	5.59	5.76	6.95	7.15	6.12	6.44	6.49	6.31	↓
5HT _{2B}	6.62	7.86	7.29	8.14	6.97	6.89	6.6	7.18	6.83	7.14	↑
5HT _{2C}	5.73	5.33	<5	5.18	5.74	5.91	5.43	5.36	5.3	5.18	=
5HT _{3A/B}	5.94	<5	<5	<5	<5	<5	<5	5.17	<5	5.56	↖
5HT _{4B}	6.65	<5	<5	<5	6.21	6.06	6.36	6.94	6.9	6.27	↖
Alpha _{1A}	6.39	<5	<5	5.11	<5	6.28	6.4	6.35	6.26	6.48	↖
Alpha _{2A}	6.05	<5	<5	<5	5.44	<5	5.11	5.32	5	5.09	↖
Alpha _{2B}	6.19	<5	<5	<5	5.6	5.58	5.22	5.6	5.47	5.28	↖
Alpha _{2C}	6	<5	<5	<5	6.02	<5	5.93	5.68	5.71	5.23	↖
D _{2L}	6.27	4.98	<5	<5	5.34	5.56	5.10	5.33	5.32	5.32	↓
hERG	7.42	5.12	<5	<5	6.63	6.54	6.5	6.5	6.75	6.72	↓

The reference compound (Ref.) is cisapride.

Example 5 : 5-HT_{2B} antagonism

CHO-K1 (ECACC) cells were stably transfected with human 5-HT_{2B} receptor cDNA subcloned into pCDNA3.1 using the calcium phosphate method. Stably transfected cell lines were selected using G-418, and clonal cell lines were developed by limit dilution.

5 Cell lines were cultured in Dulbecco's modified Eagle Medium (DMEM) containing 10% heat inactivated dialyzed foetal bovine serum (FBS), 1% penicillin-streptomycin, 1% L-glutamine and 1% non-essential amino acids.

Confluent monolayers plated into black 96 well plates with clear bottoms were loaded with 4 μ M Fluo-3-AM for 90 min at 37°C in Hanks balanced salt solution

10 supplemented with 20 mM HEPES and 2.5 mM probenecid. After washing, the test compound was added to the cells and maximal fluorescence in response to 0.1 nM serotonin was recorded using a fluorometric imaging plate reader (FLIPR) to detect changes in intracellular calcium levels.

The maximal fluorescence recorded in the presence of the test compound was

15 expressed as a percent of the maximal fluorescence response to the agonist serotonin (0.1 nM). The IC₅₀ value was determined by non-linear regression analysis of the concentration-response curves generated with mean replicate values using Hill equation curve fitting ($Y = D + [(A - D)/(1 + (C/C_{50})nH)]$, where Y = specific response, D = minimum specific response (no drugs or serotonin added), A = maximum specific

20 response (0.1 nM serotonin, no drugs), C = concentration of compound, and C₅₀ = IC₅₀, and nH = slope factor) (SigmaPlot® 4.0, SPSS Inc.). The apparent dissociation constant (K_B) was calculated using the modified Cheng Prusoff equation (K_B = IC₅₀/(1+(A/EC_{50A})), where A = concentration of serotonin, and EC_{50A} = EC₅₀ value of serotonin in this assay). (Porter et al. (1999), Br. J. Pharmacol., 128: 13-20)

25

Table 3 : 5-HT_{2B} antagonism

Compound	IC ₅₀	K _B
(\pm)-7	60 nM	20 nM
(\pm)-12	12 nM	4.2 nM
(+)-17	33 nM	11 nM
(-)-17	1.6 nM	0.55 nM

Example 6 : hERG-transfected HEK293 cells using a Patch Express apparatus.

30 Experiments were performed using HEK293 cells stably expressing the hERG potassium channel. Cells were grown at 37°C and 5% CO₂ in culture flasks in MEM Medium supplemented with 10% heat-inactivated fetal bovine serum, 1% L-

Glutamine-Penicillin-Streptomycin-solution, 1% non-essential amino acids (100x), 1% sodium pyruvate (100mM) and 0.8% Geneticin (50mg/ml). Before use the cells were subcultured in MEM medium in the absence of 5 ml L-Glutamine-Penicillin-Streptomycin. For use in the automated patch-clamp system PatchXpress 7000A (Axon Instruments) cells were harvested to obtain cell suspension of single cells.

Extracellular solution contained (mM): 150 NaCl, 4 KCl, 1 MgCl₂, 1.8 CaCl₂, 10 HEPES, 5 Glucose (pH 7.4 with NaOH). Pipette solution contained (mM): 120 KCl, 10 HEPES, 5 EGTA, 4 ATP-Mg₂, 2 MgCl₂, 0.5 CaCl₂ (pH 7.2 with KOH).

Patch-clamp experiments were performed in the voltage-clamp mode and whole-cell currents were recorded with an automated patch-clamp assay utilizing the PatchXpress 7000A system (Axon Instruments). Current signals were amplified and digitized by a Multiclamp amplifier, stored and analyzed by using the PatchXpress, DataXpress software and Igor 5.0 (Wavemetrics).

The holding potential was -80 mV. The hERG current (K⁺-selective outward current) was determined as the maximal tail current at -40 mV after a 2 second depolarization to +60 mV. Pulse cycling rate was 15 s. Before each test pulse a short pulse (0.5 s) from the holding potential to -60 mV was given to determine (linear) leak current.

After establishing whole-cell configuration and a stability period, the vehicle (aqueous DMSO control) was applied for 5 minutes followed by the test substance by increasing concentrations of 10⁻⁷ M, 3 x 10⁻⁷ M and 3 x 10⁻⁶ M.

Each concentration of the test substance was applied twice. The effect of each concentration was determined after 5 min as an average current of 3 sequential voltage pulses. To determine the extent of block the residual current was compared with vehicle pre-treatment. Data are expressed as % block at the indicated concentrations in Table 4. The values between brackets refer to % block by the vehicle.

Table 4 : % block of the hERG channel

Concentration	100 nM	300 nM	3000 nM
Cisapride	80 (7)	95 (15)	not tested
(±)-7	35 (7)	62 (15)	94 (21)
(±)-12	40 (7)	73 (15)	96 (21)
(±)-17	9 (7)	17 (15)	58 (21)
(+)-17	14 (7)	21 (10)	52 (11)
(-)-17	3(7)	11 (10)	47 (11)

Example 7: Monocrotaline-induced pulmonary arterial hypertension in the rat

Compound (-)-17 was tested in monocrotaline-induced pulmonary arterial hypertension in the rat (see e.g., Stenmark et al, 2009, Am J Physiol Lung Cell Mol Physiol 297, L1013–L1032). Measurements included: mean arterial blood pressure and right ventricular pressure in vivo, ratio of right ventricular weight to left ventricular weight plus septum as an index of right ventricular hypertrophy, pulmonary artery acceleration time, and histological assessment of muscularization of pulmonary arteries.

Monocrotaline was dissolved in 1 N HCl and then into distilled water, and pH was 10 adjusted to 7.4 using NaOH. A single dose of 60 mg/kg monocrotaline was administered subcutaneously on day 0 to three groups of male Sprague Dawley rats. The test article Compound (-)-17 was dissolved in 20% hydroxypropyl-beta-cyclodextrin with NaOH, HCl and mannitol in pyrogen-free water and administered orally by gavage (10 ml/kg) once daily from day 1 for 21 days at 10 mg/kg and 50 15 mg/kg. Plasma concentrations of Compound (-)-17 were measured 2 hours (approximate Cmax after oral dosing in rats) after the final administration on day 21. Corresponding volumes of 20% hydroxypropyl-beta-cyclodextrin vehicle were administered orally according to the same protocol in a third group of animals.

20 Three-week treatments with Compound (-)-17 at 10 mg p.o. once daily (mean plasma concentration 2 hours post-dosing at day 21 ~80 ng/ml) and at 50 mg p.o. once daily (mean plasma concentration ~1,000 ng/ml) were non-toxic, and had no effect on mean arterial blood pressure (MAP), but reduced right ventricular pressure (RVP), right ventricular hypertrophy (right ventricle/(left ventricle + septum); RV/(LV+S)), and 25 increased pulmonary artery acceleration time (PAAT) (Table 5). The mean wall thickness of small pulmonary arteries was significantly increased by monocrotaline treatment, and this thickening was reduced by a three-week treatment with Compound (-)-17 at 50 mg/kg p.o. (P=0.0539) and at 10 mg p.o. (P<0.005).

30 Table 5:

Treatment	MAP (mmHg)	RVP (mmHg)	RV/(LV+S)	PAAT (ms)
Vehicle	92.53 ± 20.18	52.45 ± 9.16	0.66 ± 0.16	11.63 ± 2.36
Compound (-)-17 10 mg/kg p.o.	93.7 ± 14.11	43.18 ± 7.38 *	0.46 ± 0.08 *	15.91 ± 2.76 *

Treatment	MAP (mmHg)	RVP (mmHg)	RV/(LV+S)	PAAT (ms)
Compound (-)-17 50 mg/kg p.o.	97.58 ± 9.74	42.85 ± 11.55 *	0.41 ± 0.08 *	15.42 ± 2.62 *

Values are mean ± SD measured at Day 21. * p < 0.05 compared to vehicle

Example 8: Cardiovascular effects in the anaesthetized guinea-pig

Female guinea-pigs were anesthetized with sodium pentobarbital (66 mg/kg i.p.) followed by a continuous i.v. infusion of 6 mg/h of sodium pentobarbital and prepared 5 for measurements of the surface electrocardiogram (ECG), heart rate and mean arterial blood pressure (see De Clerck et al, Fundam. Clin. Pharm.; 2002; 16: 125-140). Compound (-)-17 was dissolved in 20% hydroxypropyl-cyclodextrin with NaOH, HCl and mannitol in pyrogen-free water and administered intravenously (0.5ml/kg) in 10 increasing doses (0.16, 0.32, 0.64, 1.25, 2.5 and 5 mg/kg) over a period of 5 min at 15- min intervals. Plasma concentrations of Compound (-)-17 were measured at the end of each infusion. Corresponding volumes of vehicle were administered according to the same protocol in a second group of animals.

Relative to vehicle, Compound (-)-17 at 0.16 up to 5 mg/kg (total dose: 9.87 mg/kg; 15 Cmax: 11,950 ng/ml) had no relevant effect on heart rate, the duration of the PQ, QRS, QT and QTcB intervals, or on ECG morphology in the anaesthetized guinea-pig (Table 6). From 2.5 mg/kg onwards (Cmax: 6,325 ng/ml; Table 7), mean arterial blood pressure started to increase (Table 6). 20 The reference compound dofetilide (0.02 mg/kg i.v. over 1 min), given 15 min after the onset of the last infusion of vehicle, decreased heart rate and prolonged the QT and QTcB intervals.

25 Table 6: Effects of Compound (-)-17 before and at 2, 5 and 15 minutes after onset of each infusion, expressed as percentage changes relative to baseline values on heart rate (HR), mean arterial blood pressure (MBP) and on ECG parameters in anaesthetized guinea pigs. Baseline values are presented as actual units.

Parameter	HR b/min	MBP mmHg	PQ ms	QRS ms	QT ms	QTc B ms
Baseline	230	33	63	31	185	361
0.16 mg/kg @ 2'	-1%	4%	0%	-2%	0%	-1%
0.16 mg/kg @ 5'	0%	13%	1%	-2%	-1%	-1%
0.16 mg/kg @ 15'	-2%	-3%	4%	0%	1%	1%
0.32 mg/kg @ 2'	-1%	6%	2%	-2%	0%	1%
0.32 mg/kg @ 5'	-4%	2%	4%	0%	3%	1%
0.32 mg/kg @ 15'	-4%	-3%	4%	0%	4%	3%
0.64 mg/kg @ 2'	-5%	6%	5%	0%	7%	4%
0.64 mg/kg @ 5'	-2%	13%	5%	-5%	5%	2%
0.64 mg/kg @ 15'	-5%	-5%	4%	-3%	8%	4%
1.25 mg/kg @ 2'	-7%	4%	5%	-2%	8%	4%
1.25 mg/kg @ 5'	-7%	15%	6%	0%	6%	2%
1.25 mg/kg @ 15'	0%	9%	6%	-3%	2%	3%
2.5 mg/kg @ 2'	-5%	17%	7%	-3%	6%	4%
2.5 mg/kg @ 5'	-6%	21%	7%	-3%	6%	3%
2.5 mg/kg @ 15'	-4%	8%	8%	0%	6%	5%
5 mg/kg @ 2'	-3%	36%	6%	-2%	7%	5%
5 mg/kg @ 5'	-3%	34%	6%	0%	3%	2%

Values are median of n=6. Statistically significant differences (p < 0.05) are indicated in bold and italic, and were calculated on the changes from baseline in actual units.

5 **Table 7:** Median plasma levels of Compound (-)-17 (ng/ml) after administration of increasing intravenous doses of 0.16, 0.32, 0.64, 1.25, 2.5 and 5 mg/kg over periods of 5 minutes at 15-minute intervals (n=6)

Dose	0.16	0.32	0.64	1.25	2.5	5
Median	398	873	1815	3330	6325	11950

10 **Example 9: Bleomycin-induced lung fibrosis in the mouse (prophetic)**
Male C57BL/6 mice are treated intratracheally with bleomycin sulfate (aqueous solution 2.5 U/ml; 2 ml/kg BW) under isoflurane inhalation anesthesia (see e.g., Ishii Y et al, 2006. Am J Respir Crit Care Med. 174(5):550-6). Thereafter Compound (-)-17 is administered once daily for 2 weeks at 10 mg/kg and 50 mg/kg p.o. Post-mortem examination includes gross pathology, lung weights and lung histopathology on Day

15. Histopathological examination of the lungs indicates that bleomycin causes inflammation followed by fibrosis in the lungs in untreated mice.

Example 10: Pharmacokinetic evaluation in the mouse

5 For intravenous (i.v.) administration, Compound (-)-17 was dissolved in saline containing 20% (w/v) hydroxy-propyl-beta-cyclodextrin (HPbCD) at a concentration of 0.25 mg/mL and administered (10 mL/kg) to male CD1 mice (n =3) as a bolus via a tail vein at a dose level of 2.5 mg/kg. For oral (p.o.) administration, Compound (-)-17 was dissolved in water containing 20% (w/v) HPbCD at a concentration of 0.5 mg/mL and
10 administered (20 mL/kg) to male CD1 mice (n =3) via gavage at a dose level of 10 mg/kg. Blood samples were collected via a saphenous vein at serial time points up to 24 h after dosing. Plasma was obtained by centrifugation and stored at -20°C prior to analysis. Analysis was performed using liquid chromatography (LC) with tandem mass spectrometric detection (MS/MS) in positive ion mode. Compound (-)-17 was eluted
15 from a reversed phase column with a gradient of acetonitrile and water containing 0.1% (v/v) formic acid. At the time of analysis plasma samples (20 uL) were thawed and deprotonated with 200 uL of acetonitrile and centrifuged. Aliquots of the supernatant were injected onto a reversed phase UPLC column and analysed via electrospray Mass Spectrometry. Calibration standards and quality controls, analysed before and after the
20 study samples, were prepared in mouse plasma at the same time as the. The accuracy (intra branch accuracy from independent QC samples) was between 85 % and 115 % of the nominal value over the entire concentration range. Non-compartmental pharmacokinetic analysis of the plasma concentration-time curves was performed using WinNonLin to provide estimates of the plasma clearance (CLp), volume of distribution
25 at steady-state (Vss), terminal phase elimination half-life (t^{1/2}) and oral bioavailability (F), the results are summarised in Table 8.

Example 11: Pharmacokinetic evaluation in the rat

For intravenous (i.v.) administration, Compound (-)-17 was dissolved in saline
30 containing 20% (w/v) hydroxy-propyl-beta-cyclodextrin (HPbCD) at a concentration of 1 mg/mL and administered (2.5 mL/kg) to male Sprague Dawley rats (n =1) as a bolus via a saphenous vein at a dose level of 2.5 mg/kg. For oral (p.o.) administration, Compound (-)-17 was dissolved in water containing 20% (w/v) HPbCD at a concentration of 1 mg/mL and administered (10 mL/kg) to male Sprague Dawley rats
35 (n = 3) via gavage at a dose level of 10 mg/kg. Blood samples were collected via a tail vein at serial time points up to 24 h after dosing. Plasma was obtained by centrifugation and stored at -20°C prior to analysis. Analysis was performed using liquid

chromatography (LC) with tandem mass spectrometric detection (MS/MS) in positive ion mode. Compound (-)-17 was eluted from a reversed phase column with a gradient of acetonitrile and water containing 0.1% (v/v) formic acid. At the time of analysis plasma samples (50 μ L) were thawed and deprotonated with at least three volumes of 5 acetonitrile and centrifuged. Aliquots of the supernatant were injected onto a reversed phase UPLC column and analysed via electrospray Mass Spectrometry. Calibration standards and quality controls, analysed before and after the samples, were prepared in rat plasma at the same time as the study samples. The accuracy (intra branch accuracy 10 from independent QC samples) was between 85% and 115% of the nominal value over the entire concentration range. Non-compartmental pharmacokinetic analysis of the plasma concentration-time curves was performed using WinNonLin to provide estimates of the plasma clearance (CL_p), volume of distribution at steady-state (V_{ss}), terminal phase elimination half-life (t_{1/2}) and oral bioavailability (F), the results are summarised in Table 8.

15

Table 8: Non-Compartmental Pharmacokinetic Parameters for Compound (-)-17 obtained in Mouse and Rat Following i.v. and p.o. Administration of Compound (-)-17-AAA (the free base).

Parameter	Mouse	Rat
CL (mL/min/kg)	20 \pm 6	46
V _{ss} (L/kg)	1.9 \pm 0.6	3.1
t _{1/2} (h)	1.4 \pm 0.2	1.1
C _{max} (ng/mL) PO	1580 \pm 165	119 \pm 37
T _{max} (h) PO	0.5 [0.5-1.0]	0.5
AUC(0-t) (ng.h/mL) PO	4443 \pm 1093	686 \pm 254
F (%)	52	19

20

Example 12: Cardio-hemodynamic, cardio-electrophysiological, electroencephalographic and pulmonary/respiratory effects in artificially ventilated, anesthetized dogs (Beagles)

The animals were anesthetized with a mixture of 0.015 mg/kg i.v. scopolamine and 25 0.075 mg/kg i.v. lofentanil, and relaxed with succinylcholine (5 mg/kg i.v.) followed by a continuous i.v. infusion of 1.5 mg/kg/h of etomidate and small additional doses of

fentanyl (0.025 mg/kg i.v.) were given at 60 min intervals. The animals were ventilated and prepared for measurements of the surface ECG, aortic-, pulmonary- and left ventricular blood pressure, carotid blood flow, monophasic action potential, body temperature, blood gasses and EEG (see Van Deuren et al, J Pharmacol Toxicol 5 Methods; 2009; 60: 11-23). Compound (-)-17 was dissolved in 20% hydroxypropylcyclodextrin with NaOH, HCl and mannitol in pyrogen-free water and administered intravenously (1 ml/kg) in increasing doses (0.16, 0.32, 0.63, 1.25, 2.5 and 5 mg/kg) over a period of 5 min at 30-min intervals. Plasma concentrations of Compound (-)-17 were measured before and at the end of each infusion. Corresponding volumes of 10 vehicle were administered according to the same protocol in a second group of animals.

Relative to vehicle, Compound (-)-17 at 0.16 up to 5 mg/kg (total dose: 9.86 mg/kg; median Cmax: 20,375 ng/ml) had no relevant effect on heart rate (HR), pulmonary artery pressure, left ventricular end diastolic pressure, cardiac output, stroke volume, 15 pressure rate product, the duration of the PQ and QRS intervals, lung function (dynamic compliance, C_{dyn} and airway resistance, R_{aw}), body temperature or on EEG (measured by the Narcotrend®) in the anesthetized dog. From 1.25 mg/kg onwards (Cmax: 5,205 ng/ml), arterial blood pressure, vascular resistance (systemic and common carotid) and Tau (time constant of relaxation) started to increase. 20 Furthermore, at 2.5 mg/kg (Cmax: 9,550 ng/ml) LV dp/dt_{max}/pd started to decrease and at 5 mg/kg (Cmax: 20,375 ng/ml) a minor decrease was noted in the duration of QTc VDW (QT interval corrected for HR) and QTc VcT (QT interval corrected for HR and temperature).

25 Table 9: Effects of Compound (-)-17 before and at 5 and 30 minutes after onset of each infusion, expressed as percentage changes relative to vehicle, on heart rate (HR), mean arterial blood pressure (MBP), systolic (SPP) and diastolic (DPP) pulmonary pressure, left ventricular contractility (LVdp/dt_{max}) and ECG parameters (PQ, QRS and QTcV) in anesthetized beagle dogs. Baseline values are presented as actual units.

30

Parameters	HR	MBP	SPP	DPP	LVdp/dt _{max}	PQ ms	QRS	QTcV
Units	b/min	mmHg	mmHg	mmHg	mmHg/s		ms	ms
Baseline	64	103	29	12	3123	97	46	294
0.16 mg/kg @ 5'	-4%	+2%	+2%	+3%	-1%	-1%	+1%	+2%
0.16 mg/kg @ 30'	-5%	+3%	+5%	-3%	+0%	-0%	+2%	+4%
0.32 mg/kg @ 5'	-5%	+5%	+11%	+0%	+0%	-2%	+3%	+2%
0.32 mg/kg @ 30'	+3%	+2%	-3%	-8%	-4%	-2%	+4%	+1%

Parameters	HR	MBP	SPP	DPP	LVdp/dt _{max}	PQ ms	QRS	QTcV
Units	b/min	mmHg	mmHg	mmHg	mmHg/s		ms	ms
Baseline	64	103	29	12	3123	97	46	294
0.63 mg/kg @ 5'	-0%	+6%	-2%	+0%	-3%	+3%	+4%	+1%
0.63 mg/kg @ 30'	+4%	+2%	-1%	-9%	-2%	-0%	+1%	+4%
1.25 mg/kg @ 5'	-0%	+10%	-1%	-7%	-1%	+2%	+4%	+2%
1.25 mg/kg @ 30'	-3%	+0%	-9%	-12%	-5%	+2%	+2%	+1%
2.5 mg/kg @ 5'	-5%	+13%	-1%	+1%	-8%	+6%	+2%	-3%
2.5 mg/kg @ 30'	-4%	+0%	-15%	-24%	+2%	+2%	+3%	-1%
5 mg/kg @ 5'	-15%	+17%	-10%	+17%	-11%	+2%	+6%	-3%
5 mg/kg @ 30'	-14%	+0%	-7%	-5%	+2%	+2%	+3%	-2%


Values are median of n = 4. Statistically significant differences (p < 0.05) are indicated in bold and italic, and were calculated on the changes from baseline in actual units.

5 Table 10: Median plasma levels of Compound (-)-17 (ng/ml) after administration of increasing intravenous doses of 0.16, 0.32, 0.64, 1.25, 2.5 and 5 mg/kg over periods of 5 minutes at 30-minute intervals (n=4).

Dose (mg/kg)	0.16	0.32	0.64	1.25	2.5	5
Median (ng/ml)	725	1420	2540	5205	9550	20375

CLAIMS

1. A compound of Formula (I)



5 or a stereochemically isomeric form thereof, wherein

R is hydrogen or fluoro, or

an addition salt or a solvate thereof.

2. The compound according to claim 1 wherein R is fluoro and the compound is a

0 racemic mixture, or an addition salt or a solvate thereof.

3. The compound according to claim 1 wherein R is fluoro and the compound has an optical rotation $[\alpha] = -14.4^\circ$ (c=0.3, MeOH, $\lambda = 598$ nm; 20°C), or an addition salt or a solvate thereof.

4. A pharmaceutical composition comprising a therapeutically effective amount of a 5 compound as defined in any one of claims 1 to 3 and a pharmaceutically acceptable carrier.

5. A process for preparing a pharmaceutical composition as defined in claim 4, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in any one of claims 1 to 3.

20 6. Use of a compound as defined in any one of claims 1 to 3 in the treatment or prevention of pulmonary arterial hypertension, pulmonary fibrosis or irritable bowel syndrome.

7. Use of a compound as defined in any one of claims 1 to 3 for the preparation or manufacture of a medicament for treating or preventing pulmonary arterial hypertension, pulmonary fibrosis or irritable bowel syndrome.

8. Use of a compound as defined in any one of claims 1 to 3 in medicine.

9. A method of treating or preventing pulmonary arterial hypertension, pulmonary fibrosis or irritable bowel syndrome, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined in any one of claims 1 to 3.

10. A compound of Formula (I); or a pharmaceutical composition according to claim 3; or
5 a process according to claim 5; or the use according to any one of claims 6 to 8; or the method according to claim 9, substantially as herein described with reference to any one of the examples but excluding comparative examples.